Clinical Trial Update: Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating raltegravir intensification on gut microbiota in chronically HIV-1 infected individuals has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Conditions: HIV | Phase 3 | Status: COMPLETED | Results posted: 2025-04-13